<SEC-DOCUMENT>0001628280-25-017639.txt : 20250414
<SEC-HEADER>0001628280-25-017639.hdr.sgml : 20250414
<ACCEPTANCE-DATETIME>20250414133204
ACCESSION NUMBER:		0001628280-25-017639
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20250414
DATE AS OF CHANGE:		20250414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Valneva SE
		CENTRAL INDEX KEY:			0001836564
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40377
		FILM NUMBER:		25835233

	BUSINESS ADDRESS:	
		STREET 1:		6, RUE ALAIN BOMBARD
		CITY:			SAINT-HERBLAIN
		STATE:			I0
		ZIP:			44800
		BUSINESS PHONE:		33 2 28 07 37 10

	MAIL ADDRESS:	
		STREET 1:		6, RUE ALAIN BOMBARD
		CITY:			SAINT-HERBLAIN
		STATE:			I0
		ZIP:			44800
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6-kcoverpagetemplate.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if383fd469a974d61b775fa2416f7e223_1"></div><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:justify"><font><br></font></div></div><div style="padding-left:5.3pt"><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</font></div><div style="margin-top:0.4pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Washington, D.C. 20549</font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:117.17pt;padding-right:117.17pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:117.17pt;padding-right:117.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:133%">FORM 6-K</font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:117.17pt;padding-right:117.17pt;text-align:center"><font><br></font></div><div style="margin-top:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE                </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Date of Report&#58; April 14, 2025</font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:114.85pt;padding-right:114.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">001-40377</font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:114.85pt;padding-right:114.85pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-left:114.85pt;padding-right:114.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%"> Valneva SE</font></div><div style="margin-top:0.8pt;padding-left:111.72pt;padding-right:111.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Translation of registrant's name into English)</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:116.95pt;padding-right:116.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:128%">6 rue Alain Bombard</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">44800 Saint-Herblain, France</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive office)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F &#9746; Form 40-F &#9744;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58;</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58;</font></div><div style="margin-top:0.05pt;padding-right:7.85pt;text-align:justify"><font><br></font></div><div style="padding-right:7.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's &#34;home country&#34;), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:3.6pt;padding-left:5.3pt;padding-right:7.85pt;text-align:justify"><font><br></font></div><div style="padding-right:7.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in this Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-286071).</font></div><div style="padding-right:7.85pt;text-align:justify"><font><br></font></div><div style="padding-right:7.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.779%"><tr><td style="width:1.0%"></td><td style="width:13.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Exhibit 99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;padding-left:5.3pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="valnevapr14-4x2025.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">Press release dated April 14, 2025</a></font></div></td></tr></table></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.089%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div style="padding-left:5.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.952%"><tr><td style="width:1.0%"></td><td style="width:13.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">Valneva SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">                           (Registrant)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date&#58;  April 14, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; Thomas Lingelbach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">                 </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Thomas Lingelbach                          </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chief Executive Officer and President</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-right:5.2pt;text-align:right"><font><br></font></div><div style="margin-bottom:0.04pt;margin-top:0.04pt;padding-right:5.2pt;text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.04pt;margin-top:0.04pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>valnevapr14-4x2025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie97f1b62130a4f1f9a53daea9539a18b_1"></div><div style="min-height:114.48pt;width:100%"><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Valneva Receives First Marketing Authorization for IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.4pt;font-weight:700;line-height:120%;position:relative;top:-5.6pt;vertical-align:baseline">&#174; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> in a Chikungunya Endemic Country </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Saint Herblain (France), April 14, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Valneva SE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Nasdaq&#58; VALN&#59; Euronext Paris&#58; VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.4pt;font-weight:700;line-height:120%;position:relative;top:-5.6pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The ANVISA decision marks the world&#8217;s first approval of a chikungunya vaccine in an endemic country. Part of Valneva&#8217;s endemic country strategy, this endeavor is supported by the Coalition for Epidemic Preparedness Innovations (CEPI)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, with co-funding from the European Union (EU), and Instituto Butantan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to support broader access to a chikungunya vaccine in low-and-middle-income countries (LMICs).</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> is the world&#8217;s first licensed chikungunya vaccine available to address this significant unmet medical need. In addition to Brazil, IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">is approved for the prevention of disease caused by the chikungunya virus in people aged 12 years and older in the EU, and in people aged 18 years and older in the United States (U.S.)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, Canada</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and the United Kingdom (U.K.)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">. Label extension applications to adolescents were submitted in the U.S., Canada and the U.K.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This important approval primarily enables initiation of large-scale clinical trials of IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in Brazil, including the committed Phase 4 clinical trials supporting IXCHIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;s approval by the U.S. Food and Drug Administration (FDA) and the European Commission to generate additional data on vaccine effectiveness. CEPI is providing funding support to these trials.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ANVISA continues to review VLA1555, the chikungunya vaccine candidate which, if approved, will be locally manufactured and distributed by Instituto Butantan pursuant to its collaboration with Valneva. Potential approval is anticipated in mid-2025. Instituto Butantan is committed to providing a locally manufactured vaccine at an affordable price in Latin America and selected LMICs. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Valneva and Instituto Butantan are working together to ensure fast access to its chikungunya vaccines for the Brazilian market and other countries in the region as quickly as possible. The Americas saw nearly 300,000 chikungunya cases and 300 deaths attributed to the virus between January and July 2023, totaling more than 720,000 cases since 2020</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Brazil has reported the highest number of cases, with over 1 million total between January 2019 and July 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, commented, &#8220;This approval marks a crucial milestone toward making our chikungunya vaccine available to LMICs where the </font></div><div style="border-bottom:0.5pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine - Valneva</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries - Valneva</font></div><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Valneva Announces U.S. FDA Approval of World&#8217;s First Chikungunya Vaccine, IXCHIQ</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:139%;position:relative;text-decoration:underline;top:-2.8pt;vertical-align:baseline">&#174; - Valneva</font></div><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Valneva Announces Health Canada Approval of the World&#8217;s First Chikungunya Vaccine, IXCHIQ</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:139%;position:relative;text-decoration:underline;top:-2.8pt;vertical-align:baseline">&#174; - Valneva</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Valneva Receives Marketing Authorization in the UK for the World&#8217;s First Chikungunya Vaccine, IXCHIQ&#174; - Valneva</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">6</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Vaccines on the table as chikungunya outbreak intensifies in India - BlueDot</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:114.48pt;width:100%"><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">                                                                                  </font></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disease is endemic. The ongoing outbreak in Brazil underscores the fact that containing chikungunya is an international public health priority. Our vaccine is particularly well suited for LMICs, where vaccine access is often limited, due to its ability to induce a robust, long-lasting antibody response in both younger and older adults with a single vaccination. </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We would like to thank our partners CEPI and Instituto Butantan for helping us address this urgent medical need by accelerating further access to our highly differentiated vaccine.&#8221;&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="background-color:#fefefe;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dr. Esper Kall&#225;s, Director of Instituto Butantan added,</font><font style="color:#202124;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The approval of the chikungunya vaccine is a great victory for Brazil, where over 150,000 people suffer from the disease every year. It is an honor for Butantan to be able to contribute to ensuring that this vaccine reaches the population that needs it the most.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dr. Richard Hatchett, Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">commented, &#8220;As we confront the ongoing challenges posed by chikungunya, today marks a significant step forward in our collective efforts to expand access to an important vaccine to not only benefit the travelers&#8217; market but also populations in need in outbreak-affected countries, like Brazil. ANVISA&#8217;s marketing authorization of the vaccine offers new hope in the fight against the debilitating disease and allows us to make headway in our goal to protect the tens of thousands in the country who suffer from chikungunya each year. Brazil&#8217;s approval is testament to the power of collaboration, innovation and determination and should help set the world </font><font style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">up for additional approvals in other endemic regions in the near future.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supported</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by CEPI and the EU&#8217;s Horizon program, Valneva remains focused on expanding the vaccine&#8217;s access in LMICs. In December 2024, Valneva announced a new partnership with the Serum Institute of India (SII), the world&#8217;s largest manufacturer of vaccines by number of doses, enabling supply of the vaccine in Asia</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, as part of the CEPI and EU support, Valneva is conducting a Phase 2 trial in children aged 1 to 11 years in the Dominican Republic and Honduras, for which it reported positive results in January 2025. The trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group. Valneva is also expected to evaluate the vaccine in pregnant women in countries affected by chikungunya outbreaks, like Brazil</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Chikungunya</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Aedes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Between 2013 and 2023, more than 3.7 million cases were reported </font></div><div style="border-bottom:0.5pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - Valneva</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">CEPI expands partnership with Valneva with $41.3 million to support broader access to world&#8217;s first Chikungunya vaccine &#124; CEPI</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;jvi.asm.org&#47;content&#47;jvi&#47;88&#47;20&#47;11644.full.pdf</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;cmr.asm.org&#47;content&#47;31&#47;1&#47;e00104-16</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:114.48pt;width:100%"><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">                                                                                  </font></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the Americas</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">12</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Valneva SE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We have a strong track record, having advanced multiple vaccines from early R&#38;D to approvals, and currently market three proprietary travel vaccines, including the world&#8217;s first chikungunya vaccine, as well as certain third-party vaccines.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world&#8217;s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">www.valneva.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Instituto Butantan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Instituto Butantan is the main producer of immunobiological products and vaccines in Brazil. Instituto Butantan carries out scientific missions domestically and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations. The Institute is an affiliate of the S&#227;o Paulo State Secretariat of Health and cooperates with the Brazilian Ministry of Health for the improvement of overall health in Brazil. It acts in partnership with various universities and entities such as the Bill &#38; Melinda Gates Foundation for the achievement of its institutional objectives. For more information please visit the Institute website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">www.butantan.gov.br </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">or contact the press office at&#160;(+55 11) 2627-9606 &#47; 9428&#160;or email to&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">imprensa&#64;butantan.gov.br</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About CEPI</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organizations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI&#8217;s pandemic-beating five-year plan for 2022-2026 is the &#8216;100 Days Mission&#8217; to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Learn more at </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">CEPI.net</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">. Follow us on X (&#64;CEPIvaccines), </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Facebook</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="border-bottom:0.5pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> PAHO&#47;WHO data&#58; Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.paho.org&#47;data&#47;index.php&#47;en&#47;mnu-topics&#47;chikv-en&#47;550-chikv-weekly-en.html</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Last accessed 01 Aug 2023.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:114.48pt;width:100%"><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">                                                                                  </font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Horizon Europe</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Horizon Europe&#160;&#8212;&#160;#HorizonEU &#8212; is the European Union's flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of &#8364;95,5 billion to spend over a seven-year period (2021-2027).&#160;&#160;Under Horizon Europe, health research will be supported with the aim to find new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalised medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Media and Investor Relations Contacts</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:127%">Valneva </font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Laetitia Bachelot-Fontaine</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">VP Global Communications &#38; European Investor Relations</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">M +33 (0)6 4516 7099</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">laetitia.bachelot-fontaine&#64;valneva.com&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Joshua Drumm, Ph.D.</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">VP Global Investor Relations</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">M +001 917 815 4520</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">joshua.drumm&#64;valneva.com</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">CEPI</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">press&#64;cepi.net </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">+44 7387 055214</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of technology transfer and regulatory approvals in additional markets. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as &#8220;could,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;targets,&#8221; or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:114.48pt;width:100%"><div><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">                                                                                  </font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
